Related Experiment Video
Updated: Aug 3, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
A case report of severe hyponatremia secondary to Paxlovid-induced SIADH
Sarah Mohamed1, Mostafa Reda Mostafa2, Mohamed Magdi Eid2
1School of Medicine Cairo University Giza Egypt.
Abstract:
Nirmatrelvir-ritonavir (Paxlovid) is a brand-new oral antiviral medication for treating mild to severe COVID-19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir-nirmatrelvir on December 22, 2021, to treat COVID-19. We describe a case of mild COVID-19 infection who developed severe hyponatremia following the administration of Paxlovid. Clinical and laboratory evaluations suggest SIADH, likely secondary to Paxlovid. The potential side effects of this medication still require further study.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Disorder of Water Balance
Dehydration
Dehydration occurs when the body loses fluids (particularly water).
Causes:
The major causes of dehydration include excessive sweating, fever, vomiting, diarrhea, and diuresis.
Signs and Symptoms:
Symptoms primarily include intense...
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome III : Nursing Management
Diabetes Insipidus II: Pathophysiology
Hyperosmolar Hyperglycemic State

